Free Trial

Exact Sciences Q2 2023 Earnings Report

Exact Sciences logo
$59.25 -0.15 (-0.25%)
(As of 03:03 PM ET)

Exact Sciences EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.94

Exact Sciences Revenue Results

Actual Revenue
$622.10 million
Expected Revenue
$601.14 million
Beat/Miss
Beat by +$20.96 million
YoY Revenue Growth
+19.30%

Exact Sciences Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available 

Exact Sciences Earnings Headlines

Brokerages Set Exact Sciences Co. (NASDAQ:EXAS) PT at $72.94
Exact Sciences: Profitability Remains Elusive
Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Exact Sciences (EXAS) Gets a Buy from TD Cowen
See More Exact Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exact Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exact Sciences and other key companies, straight to your email.

About Exact Sciences

Exact Sciences (NASDAQ:EXAS) provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

View Exact Sciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings